দেশ: মাল্টা
ভাষা: ইংরেজি
সূত্র: Medicines Authority
Health-Med sp. z o.o. sp.j. ul. Wawelska 8/5 04-222 Warszawa, Poland
S01BA04
PREDNISOLONE 5 mg/ml
EYE DROPS, SOLUTION
PREDNISOLONE 5 mg/ml
POM
OPHTHALMOLOGICALS
Authorised
2023-09-26
1 PACKAGE LEAFLET: INFORMATION FOR THE USER MINIMS PREDNISOLONE SODIUM PHOSPHATE, 0.5% W/V EYE DROPS, SOLUTION, 5 MG/ML EYE DROPS SOLUTION IN SINGLE DOSE-CONTAINER PREDNISOLONE SODIUM PHOSPHATE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What MINIMS PREDNISOLONE SODIUM PHOSPHATE is and what it is used for 2. What you need to know before you MINIMS PREDNISOLONE SODIUM PHOSPHATE 3. How to take MINIMS PREDNISOLONE SODIUM PHOSPHATE 4. Possible side effects 5. How to store MINIMS PREDNISOLONE SODIUM PHOSPHATE 6. Contents of the pack and other information. 1. WHAT MINIMS PREDNISOLONE SODIUM PHOSPHATE IS AND WHAT IT IS USED FOR MINIMS PREDNISOLONE SODIUM PHOSPHATE contains prednisolone sodium phosphate which belongs to a group of medicines called corticosteroids. It is used to treat ocular inflammation (red and painful in eyes) for which the inflammation is not caused by an infection. The part of the eye affected will vary depending on the cause of the inflammation. This medicine is indicated for adults. MINIMS PREDNISOLONE SODIUM PHOSPHATE is not suitable for treating of eye infections. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MINIMS PREDNISOLONE SODIUM PHOSPHATE _ _ DO NOT TAKE THE MINIMS PREDNISOLONE SODIUM PHOSPHATE - If you are allergic to prednisolone or any of the other ingredients of this medicine (listed in section 6). - If you have eye infection caused by viruses, fungi or bacteria. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist if you experience blurred vision or visual disturbanc সম্পূর্ণ নথি পড়ুন
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Minims Prednisolone Sodium Phosphate 5 mg/ml eye drops, solution in single dose-container 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of eye drops solution contains 5 mg of Prednisolone Sodium Phosphate Ph. Eur. Each single dose unit contains 0.5 ml eye drops solution of 2.5 mg prednisolone sodium phosphate. Each drop contains 0.185 mg prednisolone sodium phosphate. Excipient(s) with known effect: Each ml of eye drops solution contains 3 mg of Sodium dihydrogen phosphate dihydrate For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Eye drops, solution in single-dose container Clear, colourless, sterile .eye drops, solution. pH: 7.5-8.5 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Non-infected, inflammatory conditions of the eye in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults and the elderly _ One drop should be administered into the conjunctival sac of the affected eye four times up to eight times daily, adjusted or tapered based on the severity of the condition and the patients’ response. Typically, one drop should be administered 4 times daily for 1 to 3 weeks, followed by one drop twice daily. In more severe cases, beginning with one drop 8 times daily for the first week may be considered. The use of anti-inflammatory steroidal drugs should be continued for the minimal required period needed to control the information and ophthalmological assessment should be made after 1 week or if the symptoms get worse. _ _ _Paediatric population _ The safety and efficacy of Minims Prednisolone Sodium Phosphate in children has not been established. Method of administration For ocular use only. This product is sterile when packaged. Patients should be advised not to allow the dropper tip to touch any surface, as this may contaminate the solution. Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for 1-2 minutes during and following the instillation of the drops. Th সম্পূর্ণ নথি পড়ুন